Ardelyx (ARDX) Competitors $6.38 +0.19 (+3.07%) Closing price 04:00 PM EasternExtended Trading$6.30 -0.08 (-1.18%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. NUVL, AXSM, CRSP, ABVX, MRUS, CYTK, VKTX, TGTX, KRYS, and ACADShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Nuvalent (NUVL), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Abivax (ABVX), Merus (MRUS), Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Nuvalent Axsome Therapeutics CRISPR Therapeutics Abivax Merus Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Nuvalent (NASDAQ:NUVL) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings. Which has stronger valuation and earnings, NUVL or ARDX? Ardelyx has higher revenue and earnings than Nuvalent. Ardelyx is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.90-15.51Ardelyx$386.15M3.98-$39.14M-$0.23-27.74 Do institutionals and insiders hold more shares of NUVL or ARDX? 97.3% of Nuvalent shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 10.2% of Nuvalent shares are held by insiders. Comparatively, 4.8% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer NUVL or ARDX? In the previous week, Ardelyx had 4 more articles in the media than Nuvalent. MarketBeat recorded 18 mentions for Ardelyx and 14 mentions for Nuvalent. Nuvalent's average media sentiment score of 1.54 beat Ardelyx's score of 0.70 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ardelyx 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate NUVL or ARDX? Nuvalent currently has a consensus target price of $118.91, suggesting a potential upside of 56.42%. Ardelyx has a consensus target price of $11.50, suggesting a potential upside of 80.25%. Given Ardelyx's higher possible upside, analysts plainly believe Ardelyx is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is NUVL or ARDX more profitable? Nuvalent has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Nuvalent's return on equity of -32.58% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -32.58% -30.14% Ardelyx -14.60%-36.57%-13.42% Which has more volatility & risk, NUVL or ARDX? Nuvalent has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. SummaryNuvalent beats Ardelyx on 9 of the 15 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.54B$2.79B$5.76B$9.84BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-27.7422.8231.3126.60Price / Sales3.98742.71461.30121.37Price / CashN/A177.7737.7659.36Price / Book11.006.1810.026.67Net Income-$39.14M$32.94M$3.27B$265.59M7 Day Performance4.42%0.99%3.17%3.42%1 Month Performance49.07%1.69%4.34%1.09%1 Year Performance3.74%11.45%44.11%23.85% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.1399 of 5 stars$6.38+3.1%$11.50+80.3%-0.5%$1.54B$386.15M-27.7490News CoveragePositive NewsInsider TradeNUVLNuvalent3.439 of 5 stars$75.01-1.4%$119.60+59.4%-9.7%$5.48BN/A-15.3140News CoveragePositive NewsAXSMAxsome Therapeutics4.7772 of 5 stars$111.13+1.8%$178.00+60.2%+37.0%$5.45B$385.69M-21.92380News CoveragePositive NewsInsider TradeCRSPCRISPR Therapeutics3.5205 of 5 stars$57.59-3.6%$71.60+24.3%+11.0%$5.43B$37.31M-10.61460Positive NewsAnalyst UpgradeABVXAbivax2.7265 of 5 stars$70.01-0.6%$92.33+31.9%+564.1%$5.32BN/A0.0061News CoveragePositive NewsAnalyst RevisionMRUSMerus2.3278 of 5 stars$66.00-1.9%$88.50+34.1%+26.9%$5.09B$36.13M-12.0037News CoveragePositive NewsAnalyst ForecastCYTKCytokinetics3.7387 of 5 stars$38.95+0.7%$71.58+83.8%-32.3%$4.63B$18.47M-7.64250News CoveragePositive NewsVKTXViking Therapeutics3.8982 of 5 stars$42.09+5.1%$86.92+106.5%-56.7%$4.50BN/A-27.5120TGTXTG Therapeutics4.4007 of 5 stars$27.73-1.2%$46.25+66.8%+23.6%$4.46B$329M74.95290Positive NewsKRYSKrystal Biotech4.7119 of 5 stars$146.30-2.6%$210.75+44.1%-25.5%$4.35B$290.52M29.74210ACADACADIA Pharmaceuticals4.0332 of 5 stars$25.06-1.1%$28.88+15.2%+68.7%$4.27B$957.80M18.84510Positive News Related Companies and Tools Related Companies NUVL Competitors AXSM Competitors CRSP Competitors ABVX Competitors MRUS Competitors CYTK Competitors VKTX Competitors TGTX Competitors KRYS Competitors ACAD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access